? Foxp3 ? CD25 ? . They mainly function as immunosuppressive T cells by downregulating the induction and proliferation of effector T cells, but also modulate the immune system by maintaining self-tolerance and preventing autoimmune disease. In this study, the regulatory roles of ginsenosides, one of the active components in ginseng, Panax ginseng C. A. Meyer, in Treg cell differentiation were examined. The results demonstrated that ginsenoside Rd induced Treg differentiation by upregulating Foxp3 expression and increased the generation of TGF-b1, IL-10 and IL-35. The data suggest that ginsenoside Rd may be a potential immunomodulating agent or supplement that can be applied for transplantation and autoimmune disorders.
Introduction
During T cell development, the early intrathymic precursors CD4
-CD8 -double-negative T cells differentiate into CD4
? CD8 ? double-positive T cells, undergo positive and negative selection, and give rise to CD4
? T helper cells (Th cells) or CD8
? cytotoxic T lymphocytes (CTL) [1] . Th cells help other immune cells by secreting various cytokines, while CTL induces cell death of infected cells with perforin and granzyme. Th cells have several subsets such as Th1, Th2, Th3, Th17, Th9, or Tfh (follicular helper T cells); among them, Th1 and Th2 cells have been widely studied [2] .
Recently, CD4 ? CD25 ? Foxp3 ? T cells (Treg) were found as another subset of Th cells that negatively regulate other Th cells. Transforming growth factor (TGF)-b and IL-2 make naïve T cells differentiate into Treg cells by inducing a specific transcription factor, Foxp3 [3] . Although Treg cells mainly suppress other immune cells, they help to manage immune system with IL-10, IL-35, and TGF-b to prevent the occurrence of autoantigen production, autoimmunity, and graft-versus-host disease after transplantation [4] [5] [6] . Treg cells also reduce host immunity against pathogens to prevent tissue damage from vigorous immune disease [7] . Additionally, Treg cells repress tumor antigen-specific effector T cells, and thus are currently begin tested for treating cancer by depleting Treg [8] .
Ginsenosides are one of the active components of Ginseng, Panax ginseng C. A. Meyer (Araliaceae), and can be classified into three groups: protopanaxadiol (Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2); protopanaxatriol (Re, Rf, Rg1, Rg2, Rh1); and oleanane (Ro) [9] Ginsenosides can be metabolized by acid hydrolysis in the stomach, bacterial fermentation in the intestine, or heat-processing; such processes often result in the generation of pharmacologically active or readily absorbable forms such as compound K [20-O-D-glucopyranosyl-20(S)-protopanaxadiol]. Ginsenosides have been shown to possess anti-cancer, antiatherosclerotic, anti-diabetic, and immunomodulatory effects [9] .
Although ginsenoside Rp1 has been merely reported [10] . Therefore, the regulatory roles of various ginsenosides and compound K in Treg differentiation were examined in this study.
Materials and methods

Mouse
Three to six-week-old male C57BL/6 mice were purchased from Koatech (Pyungtaek, Korea). Foxp3-GFP C57BL/6 transgenic mice express green fluorescent protein (GFP) under the control of the mouse Foxp3 (forkhead box P3) promoter, and GFP is expressed in Foxp3 ? Treg cells. The transgenic mice were used for convenience of experiments by skipping intracellular staining of Foxp3 for flow cytometry. The Foxp3 GFP? transgenic mice were kindly provided by Prof. K. W. Hwang (Chung-Ang University, Seoul, Korea).
Korean red ginseng extract and ginsenosides
Ginsenosides [Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2(S), Rh1(S), Rh2(S), Rp1] and compound K were purchased from Ambo Institute (Daejeon, Korea) and dissolved in dimethyl sulfoxide at 20 mM.
CD4
1 T cell preparation and cell culture Spleens were harvested from mice, and single cell suspensions were prepared followed by red blood cell lysis. Cells were washed with RPMI1640 (Welgene, Daegu-si, Korea) and resuspended in MACS buffer. Anti-CD4 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were added, and CD4 ? T cells were positively separated using a magnetic MidiMACS Separator (Miltenyi Biotec). The purity of CD4
? T cells was greater than 95%. The purified CD4
? T cells were cultured in RPMI1640 containing fetal bovine serum (Welgene), penicillin/streptomycin (Gibco, Grand Island, NY, USA), MEM non-essential amino acids (Corning, Corning, NY, USA), L-glutamine (Corning), HEPES (Corning), sodium pyruvate (Corning), and 2-mercaptoethanol (SigmaAldrich, St. Louis, MO, USA). To further differentiate into Treg cells, CD4
? T cells were stimulated with plate-bound anti-mouse CD3e (1 lg/mL; clone 145-2C11, eBioscience, San Diego, CA, USA) and anti-mouse CD28 (1 lg/mL; clone 37.51, eBioscience) antibodies, and IL-2 (10 ng/mL, BD Biosciences, Franklin Lakes, NJ, USA) and TGF-b1 (2.5 ng/mL) were added to the cells. The cells were cultured at 37°C in a humidified 5% CO 2 atmosphere.
Cell viability assay
CD4
? T cells (4 9 10 5 cells) were seeded into a 96-well plate and cultured in Treg differentiation conditions together with ginsenosides. After 24 h, 10 lL of MTT solution (Sigma-Aldrich) and 100 lL of 0.04 N HCl-isopropanol were added to the culture 6 h apart. Absorbance was detected at 570 nm by a microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Total RNA isolation and cDNA synthesis
? T cells were differentiated into Treg cells in the presence of ginsenosides for 3 days, and harvested for total RNA isolation and cDNA synthesis as described previously [11] . 
Enzyme-linked immunosorbent assay (ELISA) of TGF-b1
ELISA was performed to detect the secretion of TGF-b1 as previously described [16, 17] . Purified rat anti-mouse, human, pig TGF-b1 (clone A75-2, BD Biosciences), and biotinylated rat anti-mouse, human, pig TGF-b1 (clone A75-3, BD Biosciences) antibodies were used.
Flow cytometry
To detect Foxp3
? Treg cells secreting IL-10 and IL-35, 1 9 10 6 CD4 ? T cells derived from Foxp3-GFP mice were differentiated into Treg cells in the presence of ginsenoside Rd for 3 days. The Treg cells were moved into 48-well plates at 6 9 10 5 cells/well, and cultured for an additional 2 days. Before harvest, cells were stimulated with cell stimulation cocktail (eBioscience) for 4 h. Harvested cells were fixed, permeabilized with Cytofix/Cytoperm TM Fixation/Permeabilization Kit (BD Biosciences), and blocked with anti-CD16/CD32 antibody (clone 93, eBioscience). Cells were then stained with PerCP Cy5.5-conjugated anti-IL-10 antibody (clone JES5-16E3, eBioscience) and PE-conjugated anti-IL-35 antibody (clone 27537, R&D Systems, Minneapolis, MN, USA). The stained cells were detected with a FACS Calibur (BD Biosciences) and analyzed using CellQuestPro software (BD Biosciences).
Statistics
All experiments were repeated at least 3 times, and data were expressed as the mean ± standard deviation. Significance of the data was determined by Student's t test and one-way ANOVA with Tukey's post hoc test. * p \ 0.05; ** p \ 0.01; and *** p \ 0.001.
Results and discussion
Cytotoxic effects of ginsenosides on CD4 1 
T cells under Treg cell differentiation conditions
CD4
? T cells were treated with 100 lM of ginsenosides and differentiated into Treg cells. Most ginsenosides did not affect cell viability, while Rh2(S), Rp1, and compound K showed cytotoxicity at 100 lM (Fig. 1) . Because of their cytotoxicity, Rh2(S), Rp1, and compound K were excluded for subsequent experiments.
Effects of ginsenosides on Treg cell differentiation
To examine the effects of ginsenosides on Treg differentiation, diverse ginsenosides [Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2(S), Rh1(S)] were tested for Foxp3 expression. We observed that ginsenoside Rd (G-Rd) significantly upregulated the expression of Foxp3, and thus, G-Rd was used for further investigation. The data showed that the stimulatory effect of G-Rd on Treg differentiation was dose-dependent as determined by Foxp3 gene expression (Fig. 2B) , which was confirmed by increased GFP expression in the experiments using Foxp3 GFP? transgenic mice (Fig. 2C) .
Increase in the production of immunosuppressive cytokines by ginsenoside Rd treatment
To confirm the stimulatory effects of ginsenoside Rd on Treg differentiation, the production of immunosuppressive cytokines was measured. As shown in Fig. 3 , G-Rd increased the production of TGF-b, and IL-35 significantly in a dose dependent manner, while the increase in IL-10 production was observed only at 100 lM. Taken together, the increased production of immunosuppressive cytokines as well as upregulation of Foxp3
? Treg cells supports the regulatory function of G-Rd in Treg differentiation.
Wang et al. [16] reported that G-Rd had immunosuppressive effects on skin allograft rejection in rats. The exact mechanism of G-Rd in suppressing skin rejection remains unclear; however, based on our results, G-Rd suppressed allograft rejection possibly by inducing Treg cells. Although the effect of compound K on Treg differentiation could not be tested, Chen et al. [18] reported that compound K reduced adjuvant-induced arthritis by upregulating Treg cells and suppressing T cell activation in rats. As a final metabolite of protopanaxadiol-type ginsenoside by intestinal bacteria, ginsenosides with protopanaxadiol structures such as G-Rd are metabolized into compound K In conclusion, we report the function of several ginsenosides in Treg differentiation including the induction of Treg differentiation by G-Rd. Given that rapamycin and alemtuzumab, which induce Treg cells to suppress immune responses [19] , have been developed for the treatment of transplantation and multiple sclerosis, respectively, G-Rd may be a good drug candidate or supplement for transplantation and autoimmune disorders. Prospective studies will help to determine the detailed molecular mechanism of G-Rd for inducing Treg differentiation. 
